Bone marrow transplantation for sickle cell disease

Area of Science:

• Hematology
• Pediatric Medicine
• Transplantation Immunology

Background:

• Sickle cell disease (SCD) presents significant complications in children, necessitating advanced treatment strategies.
• Allogeneic bone marrow transplantation is explored as a potential curative therapy for symptomatic SCD.
• Evaluating the risks and benefits of this procedure in pediatric SCD patients is crucial.

Purpose of the Study:

• To assess the efficacy and safety of allogeneic bone marrow transplantation in children with severe sickle cell disease.
• To determine the outcomes of transplantation in pediatric patients with SCD-related complications such as stroke, acute chest syndrome, and painful crises.

Main Methods:

• A cohort of 22 children under 16 with symptomatic SCD received HLA-identical sibling marrow allografts.
• Conditioning regimen included busulfan, cyclophosphamide, and antithymocyte globulin.
• Follow-up assessed engraftment, graft rejection, survival, and disease-specific complications.

Main Results:

• Twenty of 22 patients survived, with a median follow-up of 23.9 months.
• Sixteen patients achieved stable engraftment; three experienced graft rejection with SCD recurrence.
• Survival and event-free survival at four years were 91% and 73%, respectively, with stabilization of lung function and cerebrovascular disease observed.

Conclusions:

• Allogeneic stem-cell transplantation demonstrates curative potential in young patients with symptomatic sickle cell disease.
• The procedure offers significant long-term survival benefits and can halt disease progression.
• Transplantation should be considered for pediatric SCD patients with severe complications.